Cancer Neuroscience Symposium 2024
Wednesday, February 28, 2024, 1:00 PM – Friday, March 1, 2024, 4:00 PM
MD Anderson, Houston, TX
MD Anderson Cancer Center presents a two-day hybrid symposium featuring contributions from over 30 leading international experts focused on Cancer Neuroscience. Be part of a groundbreaking scientific event that will integrate neuroscience, cancer biology and aging science to spur a wave of innovation in cancer research and care. Building on our previous meeting with over 1200 participants as well as collaborative research and discussion among our speakers,
the goal of this meeting is to explore how the interface between cancer biology and neuroscience impacts tumor development, progression and health outcomes.
This 2nd Cancer Neuroscience Symposium will leverage advances in neuroscience, as well as advances in immuno-oncology and aging. This meeting will cover emerging areas, such as neuro-immune interactions, plasticity within the tumor microenvironment, and translational research. This meeting will bring together leading experts from across the fields of neuroscience, cancer biology, immunology, and the biology of aging, as well as oncologists, surgeons, neurologists, patients and patient advocates to facilitate discussions of exciting new concepts and developments in this rapidly growing field.
CNS 2024: Satellite Meeting on Clinical Cancer Neuroscience
The 2024 Satellite Meeting of the Cancer Neuroscience Symposium will be held virtually on February 28, 2024. Talks will present translational and clinical innovations in cancer neuroscience. Speakers will discuss advances in neurotoxicities during cancer therapies, mental health and pain effects from cancer and cancer therapies, a clinical trial panel, and a meet the editor session. The satellite meeting aims to cross-fertilize the breadth of cancer neuroscience presented at the primary cancer neuroscience symposium.
Midwestern Women In Otolaryngology Symposium
Eric P. Newman Education Center @ Washington University Medical Center
St. Louis, MO United States
March 1, 2024 12:00 PM – 7:00 PM
Harvard Medical School
Technology and Innovation in Endocrine Head and Neck Surgery
March 22-23, 2024 | In-Person | Register Today
Head and neck endocrine and oncologic surgery continues to evolve through technological advancements and innovation. Optimized nerve identification and preservation has been facilitated through advancements in nerve monitoring technology and techniques. Novel methods of tissue differentiation using techniques such as autofluorescence, labeled fluorescence, optical coherence tomography and others may improve ability to identify and characterize nerves, parathyroid tissue and tumor margins, among other applications. Application of minimally invasive ablative therapies is shifting the landscape of treatment for thyroid nodules.
This 1.5-day course will cover:
Neural monitoring state of the art/SLN and continuous monitoring and neural anatomy
Ultrasound and AI
Parathyroid autofluorescence probe and camera based systems and ICG
Neural RLN intraop imaging
Optical Coherence intraop imaging
Parathyroid vascular imaging
State of the art imaged based margin assessment
The course is designed for clinicians, surgeons and researchers alike who have an interest in developing and applying innovative technologies to augment care for head and neck endocrine disorders. The course will also offer an optional hands-on practical component for learners to participate in radiofrequency ablation (RFA) using phantom models (space limited).
Technology and Innovation in Endocrine Head and Neck Surgery features Harvard Medical School faculty and prominent experts and leaders in their field.The course is led by:
Gregory W. Randolph, MD, FACS, FACE
Marika Russell, MD, FACS
In support of improving patient care, Harvard Medical School is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Harvard Medical School designates this live activity for a maximum of 11.25 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.